{"id":89,"date":"2019-10-14T02:31:08","date_gmt":"2019-10-14T06:31:08","guid":{"rendered":"http:\/\/www.creativebiomart.org\/alzheimacy\/?page_id=89"},"modified":"2019-10-15T01:32:41","modified_gmt":"2019-10-15T05:32:41","slug":"%ce%b2-site-app-cleaving-enzyme-bace","status":"publish","type":"page","link":"https:\/\/www.creativebiomart.net\/alzheimacy\/target\/abeta-amyloid-pathway-as-drug-targets\/modulation-of-amyloid-beta-production\/beta-site-app-cleaving-enzyme-bace\/","title":{"rendered":"\u03b2-site APP Cleaving Enzyme (BACE)"},"content":{"rendered":"<p>In the amyloidogenic pathway, the amyloid precursor protein (APP) is cleaved by \u03b2-secretase, a proteolytic enzyme identified as \u03b2-site APP cleaving enzyme (BACE)\u00a0or BACE1 (for distinction from its homologue BACE2). BACE1 is a type I membrane-anchored aspartic protease responsible for the first step of proteolysis of APP and was identified in 1999. BACE1\u00a0cleaves near the N-terminus of the A\u03b2 domain of APP to generate secreted APP\u03b2 (sAPP\u03b2) and a membrane-bound C-terminal fragment (C99) containing the entire A\u03b2 domain, which is a direct precursor of A\u03b2. Therefore, BACE1 is a potential target for preventing or treating Alzheimer\u2019s Disease (AD) by reducing A\u03b2 production.<\/p>\n<p class=\"ServiceShowPic\"><img decoding=\"async\" src=\"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-content\/themes\/alzheimacy\/images\/b-site-APP-Cleaving-Enzyme-BACE-1.jpg\" width=\"500\" \/><br \/>\nFigure 1. Amyloidogenic process of APP hypothesis and formation of A\u03b242. (Chaudhary A.; <em>et al<\/em>.\u00a0Current therapeutic targets for Alzheimer\u2019s Disease. <em>Journal of Biomedicine<\/em>. 2018, 3: 74-84.)<\/p>\n<p><strong>Reasons and Advantages of BACE1 as the Target of AD <\/strong><\/p>\n<ul>\n<li>BACE1 is the first enzyme to cleave APP, and the \u03b2-cleavage activity is thought to determine the total amount of A\u03b2 production.<\/li>\n<li>Genetic experiments showed that knockout of the <em>BACE1<\/em>\u00a0gene in mice did not cause obvious defects in embryonic or early-life development, and the mice reached adulthood with no apparently abnormal phenotype.<\/li>\n<li>BACE1 genetic information levels are increased in both AD patients and animal models of disease.<\/li>\n<li>The three-dimensional structure of the BACE1 catalytic domain has been identified, which facilitates structure-based drug design.<\/li>\n<\/ul>\n<p><strong>Current Situation and Challenges of BACE1 as the Target of AD <\/strong><\/p>\n<p>Among the anti-amyloid candidates identified in the recent AD pipeline, agents with the mechanism of action centered in the activity of BACE1 or <a href=\"\/alzheimacy\/target\/abeta-amyloid-pathway-as-drug-targets\/modulation-of-amyloid-beta-production\/r-secretase\/\">\u03b3-secretase<\/a>\u00a0cover nearly 40% of the total. In addition, BACE1 becomes\u00a0the favored target in the pursuit of <a href=\"\/alzheimacy\/target\/abeta-amyloid-pathway-as-drug-targets\/\">A\u03b2-centered therapeutics<\/a>\u00a0after the significant failure of early \u03b3-secretase-based drug candidates.<\/p>\n<p>Challenges in the design of BACE1 inhibitors:<\/p>\n<ul>\n<li>Candidates must satisfy the general rigid prerequisites for a drug aimed for central nervous system (CNS) penetration.<\/li>\n<li>The crystal structure of BACE1 reveals extended catalysis that challenges the design of high-affinity inhibitors.<\/li>\n<li>The selectivity towards\u00a0different aspartyl proteases is an additional attrition factor in BACE1 drug discovery. In particular, the close homology of BACE1 with BACE2 further complicates the design of specific BACE1 inhibitors.<\/li>\n<\/ul>\n<p>Nevertheless, researchers have made impressive efforts to develop effective and specific BACE1 inhibitors. For example, peptidomimetics, small molecules and fragment-based BACE1 Inhibitors (including acyl-guanidine-based inhibitors,\u00a02-aminopyridine-based inhibitors,\u00a0aminothiazine- and aminooxazoline-based inhibitors,\u00a0aminoimidazole-based inhibitors, as well as iminothiadiazinane dioxide-based inhibitors).<\/p>\n<p><strong>Development Strategy and Focus <\/strong><\/p>\n<p>Currently, available information indicates that the inhibition of BACE1 can serve as a safe and effective target for A\u03b2 reduction. Alzheimacy pays attention to BACE1 as a target for a disease modifying therapy (DMT) for AD. R&amp;D strategies are\u00a0as follows:<\/p>\n<ul>\n<li>Peptidomimetic approach<\/li>\n<li>Effective and highly selective BACE1 <a href=\"\/alzheimacy\/therapeutics\/chemical-drug\/\">small molecule inhibitor<\/a><\/li>\n<li>The mechanism of BACE1 mRNA recognition can be inhibited by utilizing <a href=\"\/alzheimacy\/therapeutics\/gene-therapy\/\">antisense therapy<\/a>. This strategy can include antisense oligonucleotides, catalytic nucleic acids and small interfering RNA (siRNA).<\/li>\n<\/ul>\n<p>Alzheimacy\u00a0is concerned with the\u00a0BACE1 small molecule inhibitor because of its good bioavailability and blood-brain barrier penetration. Not only do we have to explore potency and PK properties, but we also conduct selectivity studies to find compounds with high selectivity to BACE1.<\/p>\n<p>In addition, as a prerequisite for evaluating, preventing or compensating for the potential adverse effects of BACE1 inhibition, we hope to improve understanding of the biology of BACE1 and the relationship between BACE1 inhibition, A\u03b2\u00a0levels, and AD cognitive deficits through <a href=\"\/alzheimacy\/solutions\/basic-research\/\"><span data-mce-type=\"bookmark\" style=\"display: inline-block; width: 0px; overflow: hidden; line-height: 0;\" class=\"mce_SELRES_start\">\ufeff<\/span>basic research<\/a>. If you are interested in this and looking forward to technical support, please feel free to <a href=\"\/alzheimacy\/contact-us\/\">contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the amyloidogenic pathway, the amyloid precursor protein (APP) is cleaved by \u03b2-secretase, a proteolytic enzyme identified as \u03b2-site APP cleaving enzyme (BACE)\u00a0or BACE1 (for distinction from its homologue BACE2). BACE1 is a type I membrane-anchored aspartic protease responsible for the first step of proteolysis of APP and was identified in 1999. BACE1\u00a0cleaves near the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":87,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/pages\/89"}],"collection":[{"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/comments?post=89"}],"version-history":[{"count":5,"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/pages\/89\/revisions"}],"predecessor-version":[{"id":139,"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/pages\/89\/revisions\/139"}],"up":[{"embeddable":true,"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/pages\/87"}],"wp:attachment":[{"href":"https:\/\/www.creativebiomart.net\/alzheimacy\/wp-json\/wp\/v2\/media?parent=89"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}